Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 9/20 | 0.42 |
| ▸ | NPY5R | Q15761 | 6/20 | 0.42 |
| ▸ | NPY1R | P25929 | 6/20 | 0.42 |
| ▸ | NPY2R | P49146 | 3/20 | 0.42 |
| ▸ | MMP1 | P03956 | 2/20 | 0.40 |
| ▸ | MMP2 | P08253 | 2/20 | 0.40 |
| ▸ | MMP3 | P08254 | 2/20 | 0.40 |
| ▸ | NMT1 | P30419 | 5/20 | 0.40 |
| ▸ | NMT2 | O60551 | 4/20 | 0.40 |
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10303436 | 0.90 | NPY4R (0.43) | NPY4RNPY5RNPY1RNPY2RMMP1 | |
| SCHEMBL10303447 | 0.90 | NPY4R (0.40) | NPY4RNPY5RNPY1RNPY2RMMP1 | |
| SCHEMBL10303439 | 0.89 | MMP1 (0.42) | NPY4RNPY5RNPY1RNPY2RMMP1 | |
| SCHEMBL10303440 | 0.83 | NPY2R (0.41) | NPY4RNPY5RNPY1RNPY2RMMP1 | |
| SCHEMBL12340430 | 0.82 | IL23R (0.37) | NPY4RNPY5RNPY1RNPY2RMMP1 | |
| SCHEMBL30857468 | 0.81 | MMP1 (0.43) | NPY4RNPY5RNPY1RNPY2RMMP1 | |
| SCHEMBL30528168 | 0.80 | NPY4R (0.45) | NPY4RNPY5RNPY1RNPY2RMMP1 | |
| SCHEMBL30658144 | 0.80 | CPB2 (0.47) | NPY4RNPY5RNPY1RNPY2RNMT1 | |
| Hydrochloric Acid SCHEMBL31021035 | 0.79 | NPY4R (0.44) | NPY4RNPY5RNPY1RNPY2RMMP1 | |
| Hydrochloric Acid SCHEMBL31021010 | 0.79 | NPY4R (0.48) | NPY4RNPY5RNPY1RNPY2RMMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9260500-B2 | Peptide and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-02-16 | — | — | US | disclosed |
| US-20120172293-A1 | PEPTIDE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2012-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120172293-A1 | PEPTIDE AND USE THEREOF | GLP1R, GIPR, SCTR | NPY4R 4/4885NPY5R 6/4885NPY1R 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.